SPRO vs. ONCY, CMRX, QTTB, BRNS, PRPH, VACC, BTAI, MIST, MRNS, and ANIX
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Oncolytics Biotech (ONCY), Chimerix (CMRX), Q32 Bio (QTTB), Barinthus Biotherapeutics (BRNS), ProPhase Labs (PRPH), Vaccitech (VACC), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), Marinus Pharmaceuticals (MRNS), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Spero Therapeutics has a net margin of 21.09% compared to Spero Therapeutics' net margin of 0.00%. Oncolytics Biotech's return on equity of 35.42% beat Spero Therapeutics' return on equity.
Oncolytics Biotech presently has a consensus price target of $4.00, indicating a potential upside of 260.36%. Spero Therapeutics has a consensus price target of $7.00, indicating a potential upside of 340.25%. Given Oncolytics Biotech's higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Oncolytics Biotech.
Spero Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Spero Therapeutics received 48 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 69.31% of users gave Spero Therapeutics an outperform vote while only 68.30% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
In the previous week, Oncolytics Biotech had 10 more articles in the media than Spero Therapeutics. MarketBeat recorded 19 mentions for Oncolytics Biotech and 9 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.33 beat Oncolytics Biotech's score of -0.17 indicating that Oncolytics Biotech is being referred to more favorably in the media.
Summary
Spero Therapeutics beats Oncolytics Biotech on 12 of the 16 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
